Sucampo Pharmaceuticals, Inc. Files For Initial Public Offering

BETHESDA, Md., June 19 /PRNewswire/ -- Sucampo Pharmaceuticals, Inc, announced today that it has filed a registration statement with the Securities and Exchange Commission for the initial public offering of its class A common stock. The number of shares to be offered and the price range for the offering have not yet been determined.

Banc of America Securities LLC and Deutsche Bank Securities Inc. will serve as joint book-runners and lead managers for the offering. Leerink Swann & Company will be the co-manager for the offering.

Sucampo is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this offering may be obtained from Banc of America Securities LLC, Capital Markets (Prospectus Fulfillment) by e-mail to dg.prospectus_distribution@bofasecurities.com or by mail to Banc of America Securities LLC, Capital Markets Operations, 100 West 33rd Street, 3rd Floor, New York, NY 10001.

Sucampo Pharmaceuticals, Inc

CONTACT: Robert R. Gillispie, General Counsel of Sucampo Pharmaceuticals,Inc, +1-301-961-3400, or rgillispie@sucampo.com

Back to news